Literature DB >> 19125898

Inhaled corticosteroids for asthma: are they all the same?

A P Baptist1, R C Reddy.   

Abstract

OBJECTIVES: To assess similarities and differences among currently available inhaled corticosteroids (ICS) for treatment of asthma, with special emphasis on factors that may affect the relative safety of these medications.
METHODS: PubMed was searched for relevant reviews and original articles. Information from these studies was synthesized and critically assessed.
RESULTS: Differences in corticosteroid formulations and delivery systems can create variations in therapeutic efficacy. Chemical properties of the various corticosteroids may also affect their relative safety. Ciclesonide and beclomethasone dipropionate are administered as prodrugs activated by enzymes present in the lungs but not the oropharynx. Corticosteroid-specific adverse effects in the oropharynx are thus avoided, although formulation-specific effects may remain. Other adverse effects require systemic availability, either via the gastrointestinal tract or the lung. Once they enter the systemic circulation, all ICS are rapidly metabolized by the liver. Oral bioavailability of ICS such as fluticasone, ciclesonide and mometasone is minimal, as a result of their essentially complete first-pass metabolism in the liver. Ciclesonide also undergoes extrahepatic metabolism that eliminates it even more rapidly. Additionally, ciclesonide and mometasone exhibit very high levels of binding to serum proteins that reduces their ability to stimulate glucocorticoid receptors outside the lung.
CONCLUSIONS: Despite acting by similar mechanisms, currently available ICS and their delivery systems differ in ways that can potentially affect both safety and therapeutic effectiveness for individual patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19125898     DOI: 10.1111/j.1365-2710.2008.00970.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  11 in total

1.  Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations.

Authors:  Ritesh Agarwal; Sahajal Dhooria; Ashutosh Nath Aggarwal; Venkata N Maturu; Inderpaul S Sehgal; Valliappan Muthu; Kuruswamy T Prasad; Lakshmikant B Yenge; Navneet Singh; Digambar Behera; Surinder K Jindal; Dheeraj Gupta; Thanagakunam Balamugesh; Ashish Bhalla; Dhruva Chaudhry; Sunil K Chhabra; Ramesh Chokhani; Vishal Chopra; Devendra S Dadhwal; George D'Souza; Mandeep Garg; Shailendra N Gaur; Bharat Gopal; Aloke G Ghoshal; Randeep Guleria; Krishna B Gupta; Indranil Haldar; Sanjay Jain; Nirmal K Jain; Vikram K Jain; Ashok K Janmeja; Surya Kant; Surender Kashyap; Gopi C Khilnani; Jai Kishan; Raj Kumar; Parvaiz A Koul; Ashok Mahashur; Amit K Mandal; Samir Malhotra; Sabir Mohammed; Prasanta R Mohapatra; Dharmesh Patel; Rajendra Prasad; Pallab Ray; Jai K Samaria; Potsangbam Sarat Singh; Honey Sawhney; Nusrat Shafiq; Navneet Sharma; Updesh Pal S Sidhu; Rupak Singla; Jagdish C Suri; Deepak Talwar; Subhash Varma
Journal:  Lung India       Date:  2015-04

2.  Effectiveness and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma in medical practice (Data from a non-interventional study conducted in Austria).

Authors:  Otto Chris Burghuber; Gerhard Köberl; Susanna Lenk-Feik; Monika Schantl; Peter Sander; Alexandra Hammer
Journal:  Wien Klin Wochenschr       Date:  2014-08-15       Impact factor: 1.704

3.  Value of inhaled corticosteroid therapy in long-term asthma management.

Authors:  Donald S Beam
Journal:  P T       Date:  2010-07

4.  Dexamethasone-induced FKBP51 expression in peripheral blood mononuclear cells could play a role in predicting the response of asthmatics to treatment with corticosteroids.

Authors:  Eunyoung Chun; Hyun-Seung Lee; Bo-Ram Bang; Tae-Wan Kim; So-Hee Lee; Ju-Han Kim; Sang-Heon Cho; Kyung-Up Min; You-Young Kim; Heung-Woo Park
Journal:  J Clin Immunol       Date:  2010-09-18       Impact factor: 8.317

5.  Steroid-induced Deficiency of Mucosal-associated Invariant T Cells in the Chronic Obstructive Pulmonary Disease Lung. Implications for Nontypeable Haemophilus influenzae Infection.

Authors:  Timothy S C Hinks; Joshua C Wallington; Anthony P Williams; Ratko Djukanović; Karl J Staples; Tom M A Wilkinson
Journal:  Am J Respir Crit Care Med       Date:  2016-11-15       Impact factor: 21.405

6.  Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy.

Authors:  Alexandra Ahmet; Harold Kim; Sheldon Spier
Journal:  Allergy Asthma Clin Immunol       Date:  2011-08-25       Impact factor: 3.406

Review 7.  Fracture prevention in COPD patients; a clinical 5-step approach.

Authors:  Elisabeth A P M Romme; Piet Geusens; Willem F Lems; Erica P A Rutten; Frank W J M Smeenk; Joop P W van den Bergh; Peter ThW van Hal; Emiel F M Wouters
Journal:  Respir Res       Date:  2015-03-07

Review 8.  Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors:  Arnulf Langhammer; Siri Forsmo; Unni Syversen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19

9.  Comparison of Effectiveness between Beclomethasone Dipropionate and Fluticasone Propionate in Treatment of Children with Moderate Asthma.

Authors:  Akefeh Ahmadiafshar; Mohsen Mogimi Hadji; Nima Rezaei
Journal:  World Allergy Organ J       Date:  2010-10       Impact factor: 4.084

10.  Comparative effectiveness of inhaled corticosteroids for paediatric asthma: protocol for a systematic review and Bayesian network meta-analysis.

Authors:  Masato Takeuchi; Hirotsugu Kano; Kenzo Takahashi; Tsutomu Iwata
Journal:  BMJ Open       Date:  2015-10-22       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.